Visceral Pain Reduction
Visceral Pain Reduction - Related Videos
11:46
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
0 Views •
Cited by 19 •
2014
Approximately 3-8 million people in the United States suffer from interstitial cystitis/bladder pain syndrome (IC/BPS), a debilitating condition characterized in part by pelvic pain. In order to study nervous system contributions to the condition, a physiological model of urinary bladder pain is used in mice and rats.
13:32
Abdominal Exam IV: Acute Abdominal Pain Assessment
0 Views •
2023
Source: Joseph Donroe, MD, Internal Medicine and Pediatrics, Yale School of Medicine, New Haven, CT Abdominal pain is a frequent presenting concern in both the emergency department and the office setting. Acute abdominal pain is defined as pain lasting less than seven days, while an acute abdomen refers to the abrupt onset of severe abdominal pain with features suggesting a surgically intervenable process. The differential diagnosis of acute abdominal pain is broad; thus, clinicians must have a...
03:11
Oxidation-Reduction Reactions
0 Views •
2020
Oxidation–Reduction Reactions Earth’s atmosphere contains about 20% molecular oxygen, O2, a chemically reactive gas that plays an essential role in the metabolism of aerobic organisms and in many environmental processes that shape the world. The term oxidation was originally used to describe chemical reactions involving O2, but its meaning has evolved to refer to a broad and important reaction class known as oxidation–reduction (redox) reactions. Some redox reactions involve the transfer of...
14:56
An Experimental Paradigm for the Prediction of Post-Operative Pain (PPOP)
0 Views •
Cited by 107 •
2010
Diffuse noxious inhibitory control, temporal summation and wound hyperalgesia testing are demonstrated in the obstetric patient. These tests evaluate inhibitory and excitatory mechanisms of pain processing and are here utilized to evaluate endogenous analgesia at different time-points during pregnancy and the peripartum period to help reveal individual s risk for persistent pain.
08:30
Intra-articular Shoulder Injection for Reduction Following Shoulder Dislocation
0 Views •
2023
Source: Rachel Liu, BAO, MBBCh, Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA The anterior shoulder dislocation is one of the most common joint dislocations seen in emergency settings. In anterior shoulder dislocation, the humeral head is displaced out of the glenohumeral joint in front of the scapular glenoid, resulting in a loss of the articulation between the arm and the rest of the shoulder. This can be caused by a fall onto an abducted, extended, and externally...
FAQs
Nonsteroidal anti-inflammatory drugs act by reducing prostaglandin production, thereby targeting a peripheral mediator associated with inflammatory pain. This mechanism is especially relevant when internal-organ pain accompanies inflammation rather than being driven primarily by smooth-muscle spasm or central processing. Their role illustrates how pharmacological intervention can modify pain-generating signals before they are integrated by the nervous system.
Opioid agonists suppress nociceptive transmission through opioid receptors, addressing the way painful signals are relayed and processed. Because this action relates to nervous-system transmission rather than only local inflammation or contraction, it represents a different strategy from anti-inflammatory or antispasmodic treatment. In pharmacology, this distinction helps explain why several drug classes may influence the same symptom through separate pathways.
Antispasmodic agents lessen pain linked to abnormal smooth-muscle contraction. Their value is greatest when spasm is a prominent contributor, because they address a mechanical or contractile source rather than primarily reducing prostaglandin production or suppressing nociceptive transmission. This mechanism supports more targeted symptom control in visceral pain states associated with abnormal organ contraction.
Treatment selection can be informed by the process contributing most strongly to the pain. Inflammation points toward reduced prostaglandin production, abnormal contraction toward antispasmodic action, and nociceptive transmission toward opioid receptor activity. Linking a drug mechanism to the relevant pain pathway helps pharmacology move beyond general symptom suppression and supports the development of safer, more targeted analgesic strategies.
These approaches support symptom control across gastrointestinal, urinary, and reproductive disorders. The relevant drug strategy may depend on whether pain accompanies inflammation, distension, or smooth-muscle spasm, although the available source does not specify individual diagnoses or treatment regimens. This broad organ-system relevance makes visceral pain reduction an important application area within pharmacology.
It demonstrates that pain from internal organs can be influenced at multiple levels. Peripheral mediators such as prostaglandins can be targeted, abnormal organ contraction can be reduced, and opioid receptors can alter nociceptive transmission within nervous-system processing. Studying these levels helps researchers interpret treatment outcomes and identify opportunities for analgesics that act more selectively on the underlying pathway.